Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662436 | 1.00 | CPB2 (0.40) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL3662433 | 1.00 | CPB2 (0.40) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL2211497 | 0.95 | CPB2 (0.42) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL1039473 | 0.95 | CPB2 (0.42) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL7416589 | 0.95 | CPB2 (0.42) | CPB2MEN1GAAKMT2ATPSAB1 | |
| Ethylenediamine SCHEMBL17669759 | 0.94 | CPB2 (0.41) | CPB2MEN1GAAKMT2ATPSAB1 | |
| Ethylenediamine SCHEMBL17669758 | 0.94 | CPB2 (0.41) | CPB2MEN1GAAKMT2ATPSAB1 | |
| Glycerin SCHEMBL28491442 | 0.92 | CPB2 (0.34) | CPB2MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL20743469 | 0.85 | MEN1 (0.38) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL20743467 | 0.85 | MEN1 (0.38) | MEN1GAAKMT2ATPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-2285772-B1 | NEW CLASS OF CATIONIC LIPIDS FOR TRANSPORTING ACTIVE AGENTS INTO CELLS | OZ BIOSCIENCES SAS (FR) | 2022-07-13 | — | — | EP | disclosed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-2743270-B1 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER IP GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-2222686-B1 | POLYVIOLOGEN BORONIC ACID QUENCHERS FOR USE IN ANALYTE SENSORS | MEDTRONIC MINIMED INC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2379540-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20140296515-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8772498-B2 | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2743270-A1 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | Bayer Intellectual Property GmbH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| EP-0869937-A4 | NOVEL AMIDE-BASED CATIONIC LIPIDS | PROMEGA BIOSCIENCES INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6638529-B2 | Lipid copound for use in the transfer macromolecules in cells | GENTA INCORPORATED | 2003-10-28 | — | — | US | disclosed |
| US-20020156237-A1 | Novel amide-based cationic lipids | PROMEGA BIOSCIENCES, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6339173-B1 | FOR INTERFERING WITH PROTEIN EXPRESSION IN A CELL; USEFUL IN LIPID AGGREGATES FOR THE DELIVERY OF MACROMOLECULES INTO CELLS | PROMEGA BIOSCIENCES, INC. | 2002-01-15 | — | — | US | disclosed |
| EP-0869937-A1 | NOVEL AMIDE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997003939-A9 | NOVEL AMIDE-BASED CATIONIC LIPIDS | — | 1997-05-22 | — | — | WO | disclosed |
| WO-1997003939-A1 | NOVEL AMIDE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1997-02-06 | — | — | WO | disclosed |
| US-4795595-A | Taurine derivatives | FARMITALIA CARLO ERBA S.P.A. (IT) | 1989-01-03 | — | — | US | disclosed |
| EP-0001774-A1 | Derivatives of BPTI (basic pancreatic trypsin-inhibitor), process for their preparation and their use as medicines | BAYER AG (DE) | 1979-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156237-A1 | Novel amide-based cationic lipids | CETP, SGMS1, CERT1 | CPB2 2834/4885MEN1 2351/4885GAA 3532/4885 |
| US-20140296515-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | AADAT, DDC, DNPEP | CPB2 867/4885MEN1 1799/4885GAA 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.